Full Press Release Details
Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
April 04, 2024 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the manufacturing,
development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced additional preclinical
data demonstrating INM-901's positive pharmacological effects in the potential treatment of Alzheimer's disease ("AD").
Dr. Eric Hsu, Senior
Vice President of Preclinical Research and Development at InMed, stated, "The recent results demonstrating pharmacological effects
in in vivo disease models continue to validate INM-901 as a potential treatment of AD. We are particularly encouraged with indications
that INM-901 has multiple potential mechanisms of action as a preferential signaling agonist for both cannabinoid 1 ("CB1")
and cannabinoid 2 ("CB2") receptors, as well as impacting the peroxisome proliferator-activated receptor ("PPAR")
signaling pathway. There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms
may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation,
neuroprotection and neuritogenesis."
Several preclinical studies
were conducted in well-characterized AD models. A summary of recent INM-901 preclinical study results includes:
Previous studies of INM-901 showed the
potential to target several biological pathways associated with AD, including neuroprotection to the differentiated neuronal cells from
beta-amyloid peptide-induced toxicity and improvement of neuronal function via extension of neurite length, a potential breakthrough in
the treatment of AD.
The Role of CB1, CB2 and PPAR in
the treatment of Alzheimer's
CB1 and CB2 receptors are both part
of the endocannabinoid system and are found throughout the body, including in the brain. CB1 receptors are primarily located in the central
nervous system, particularly in areas involved in memory, cognition and motor function, while CB2 receptors are involved in modulating
neuroinflammation and immune responses.
Activation of CB1 and CB2 receptors
has been shown to have neuroprotective effects, meaning they can help protect brain cells from damage and death. In AD, where neuronal
death is a hallmark feature, enhancing the activity of these receptors may help to slow down the progression of the disease. Activation
of these receptors and other cellular receptors has also been shown to have an impact on neuroinflammation. As neuroinflammation is also
believed to contribute to the progression of AD, targeting these receptors could help alleviate this inflammatory response. While further
research is needed to fully understand the role of CB1 and CB2 receptors in AD, INM-901 could offer novel therapeutic strategies for the
treatment of this devastating condition. (1)(2)
Peroxisome proliferator-activated receptors
("PPARs") are also considered potential therapeutic targets for neurodegenerative disorders such as AD. PPAR's are ligand-activated
transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: alpha ("PPAR- "),
gamma ("PPAR- "), and beta/delta ("PPAR- / "). Activation of PPAR- reduces triglyceride
level and is involved in regulation of energy homeostasis. Activation of PPAR- causes insulin sensitization and enhances glucose
metabolism, whereas activation of PPAR- / enhances fatty acids metabolism. (3)(4)
Next steps advancing preclinical
InMed intends to accelerate the development
of its AD program. Long-term behavioural and mechanism of action / receptor interaction studies are underway with data read-out expected
in calendar 3Q 2024. Development of the chemistry, manufacturing and controls ("CMC") for drug substance and oral drug product
formulation are on-going.
options for Alzheimer's disease - a major unmet medical need
Approved AD medications primarily address
symptoms related to memory and cognitive function via the reduction of beta-amyloid plaques. These medications are aimed at removing amyloid
plaque build-up between the neurons in the brain; however, they do not actively restore or rebuild deteriorating neurons and, thus, do
not reverse AD progression. In addition, use of these treatments can be limited due to significant side effects, including inflammation
and bleeding in the brain. Several large pharmaceutical companies such as Eli Lilly, Roche, AbbVie, Eisai and Biogen lead research and
commercialization efforts in AD drug development.
Learn more about InMed's INM-901 program:
Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid
analogs. Together with our subsidiary, BayMedica LLC, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum
of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid
therapeutics with programs in Alzheimer's disease, age-related macular degeneration, glaucoma, and epidermolysis bullosa. For more
information, visit www.inmedpharma.com.
Investor Relations and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects",
"anticipates", "believes", "intends", "potential", "possible", "would"
and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks,
uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's
current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: the
efficacy of INM-901, INM-901's ability to treat AD, marketability and uses for INM-901, the results of further studies into INM-901
and acceleration of the development of InMed's AD program.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks
and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings
with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.